Welcome to another edition of Core Biotech!I started this portfolio with the objective of proving that Long-Term investing in the biotech sector is a worthwhile endeavor.New buys and sells are ...

Quite a few bigwigs in the biotech sector have reported results for the fourth quarter and the picture is ordinary. While results have been mixed, the outlook provided by most of these companies is ...

The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the ...

Following the sale, iShares Biotechnology ETF is comprised 2.67% of DAFNA Capital’s 13F reportable assets under management. Top five holdings after the filing: NASDAQ:RVMD: $48.15 million (11.3% of ...

Nine months after closing a $450 million fundraise, Atlas Venture is back with another biotech financing vehicle, raising $400 million this time. The money, which Atlas has dubbed its Opportunity Fund ...

The Doris Duke Foundation’s long biotechnology bet is paying off after a five-year winter. The $2.2 billion portfolio has steadily expanded its exposure to health and life sciences as part of a ...

A solid rally on Friday salvage something from a down week that saw the NASDAQ fall 3.5%, while the Dow and S&P 500 both were off one percent. Increasing worries about tariffs and a softening economy ...

The macroenvironment in 2025 looks grim as signs of a slowdown in the economy set in. The biotech industry experienced a choppy ride in 2024, and the same is likely in store in 2025. Given the ...